Dräger Medical adopts Masimo Rainbow SET as its standard oximetry platform. The two companies also released each
other from any potential patent infringement claims on pulse oximetry
Irvine, California-November 8, 2006-Dräger Medical
AG & Co. KG today announced that it has expanded its relationship
with Masimo and will integrate Masimo Rainbow SET platform as its
principal pulse oximetry technology. The Rainbow SET platform offers
Masimo SET Read-Through Motion and Low Perfusion pulse oximetry plus
upgradeability to add other parameters in the future. Upgrades are
available today for carboxyhemoglobin (carbon monoxide) and
methemoglobin and others are planned for the future. Dräger Medical
will be incorporating Masimo Rainbow SET into major acute care
products. For future product developments, Dräger Medical will replace
its Oxisure+ oximetry with Masimo technology. This agreement between
Dräger Medical and Masimo also constitutes a release of each other from
any potential patent infringement claims relating to pulse oximetry.
Dr. Wolfgang Reim, President and CEO of Dräger Medical stated, "We
are excited to be able to extend our existing relationship and again be
one of the first companies to provide our customers with the latest
advancements in noninvasive patient monitoring technology. Masimo SET
is clearly the gold standard in motion tolerant pulse oximetry
technology and with its new Rainbow Technology Masimo extends the reach
of its technology to new important parameters. Dräger Medical and
Masimo have enjoyed a great partnership that we are very happy to
expand."
Joe E. Kiani, Chairman and CEO of Masimo stated, "We greatly value
our relationship with Dräger Medical and are happy to be expanding our
relationship with this new agreement. Dräger Medical's leadership in
patient monitoring and therapeutic systems is well recognized by
numerous customers around the world. We are delighted to see Dräger
Medical taking Masimo Rainbow SET to its customers, and thereby
improving care of millions of patients."
About Dräger Medical
Dräger Medical AG & Co. KG is one of the world's leading
manufacturers of medical equipment, the largest division of Drägerwerk
AG (history dates back to 1889) and a 65:35 joint venture company
between Drägerwerk AG and Siemens AG. The global Company offers
products, services and integrated CareArea™ Solutions throughout the
patient care process - Emergency Care, Perioperative Care, Critical
Care, Perinatal Care and Home Care. With headquarters in Lübeck,
Germany, Dräger Medical employs nearly 6,000 people worldwide, around
half of whom work in customer sales & services. R&D and
production are located in Lübeck, Germany; Best, Netherlands; Telford,
PA, and Andover, MA, USA; and Shanghai, China. The Company has sales
and service subsidiaries in almost 50 countries and is represented in
more than 190 countries. Dräger Medical provides innovative solutions
for acute patient care, which are the result of a clear focus on core
competencies, a close dialog with customers, over a century of
experience in the market, and continuous investment in R&D.
Additional information is available on the Company's website www.draeger.com
About
Masimo
Masimo develops innovative monitoring technologies that
significantly improve patient care-helping solve "unsolvable" problems.
In 1995, the company debuted Read-Through Motion and Low Perfusion
pulse oximetry, known as SET, and with it virtually eliminated false
alarms and increased pulse oximetry's ability to detect
life-threatening events. More than 100 independent clinical studies
have confirmed that Masimo SET technology allows clinicians to
accurately monitor blood oxygen saturation in critical care
situations-establishing the technology as the "gold standard" pulse
oximetry and substantially contributing to improved patient outcomes.
In 2005 Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which,
for the first time, noninvasively monitors the level of carbon monoxide
and methemoglobin in the blood, allowing early detection and treatment
of potentially life-threatening conditions. Masimo, founded in 1989,
has the mission of "Improving Patient Outcome and Reducing Cost of Care
by Taking Noninvasive Monitoring to New Sites and Applications."
Additional information about Masimo and its products may be found at www.masimo.com.
Contact:
Claudia Büring, Head of Public Relations at Dräger Medical
Phone: +49-451-882-1986
Email: claudia.buering@draeger.com
Tom McCall, Vice President, Corporate
Communications at Masimo Corporation
Phone: 1- 949-297-7075
Email: tmccall@masimo.com